文献速递白血病淋巴瘤造血干细胞移植与细胞治疗

CD19 CAR-T细胞治疗儿童复发急性淋巴细胞白血病伴活动性中枢神经系统受累:一项回顾性国际研究

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
PubMed 文献 · Leukemia · 2022-04-25

这项回顾性国际研究纳入55例转诊时中枢神经系统受累的复发B细胞前体急性淋巴细胞白血病儿童和青少年,所有患者接受桥接治疗,16例在淋巴细胞清除时仍有活动性中枢神经系统疾病。51/54例可评估患者(94%)获得完全缓解,但22例复发,其中19/43例发生在4-1BB CAR-T后(12例中枢神经系统复发),3/12例发生在CD28 CAR-T后续造血干细胞移植后(无中枢神经系统复发)。

要点

  • 51/54例可评估患者(94%)获得完全缓解
  • 细胞因子释放综合征和神经毒性发生率分别为65%和38%
  • 22例复发:4-1BB CAR-T后19/43例(12例中枢神经系统复发),CD28 CAR-T后续造血干细胞移植后3/12例(无中枢神经系统复发)

核心结论

  • CAR-T细胞在该队列中有效,但中枢神经系统复发风险未被完全消除

研究设计与样本

  • 回顾性国际研究,纳入55例转诊时中枢神经系统受累的复发B细胞前体急性淋巴细胞白血病儿童和青少年

主要发现

  • 所有患者接受桥接治疗,16例在淋巴细胞清除时仍有活动性中枢神经系统疾病
  • 12例接受CD28 CAR-T细胞,其中9例后续接受异基因造血干细胞移植;43例接受4-1BB CAR-T细胞
  • 细胞因子释放综合征和神经毒性发生率分别为65%和38%,CD28 CAR-T后更常见
  • 51/54例可评估患者(94%)获得完全缓解
  • 22例复发:4-1BB CAR-T后19/43例(12例中枢神经系统复发),CD28 CAR-T后续造血干细胞移植后3/12例(无中枢神经系统复发)

关键数值与推荐

  • 51/54例可评估患者(94%)获得完全缓解
  • 细胞因子释放综合征发生率65%,神经毒性发生率38%
  • 22例复发:4-1BB CAR-T后19/43例(12例中枢神经系统复发),CD28 CAR-T后续造血干细胞移植后3/12例(无中枢神经系统复发)
  • 因孤立性中枢神经系统复发接受替沙基因莱奥库尔治疗的患者后续中枢神经系统复发发生率高(8例中6例)

临床怎么用

  • 原文未据此给出推荐

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) may occur in the central nervous system (CNS). Most clinical trials of CAR T-cell therapy excluded patients with active CNS leukemia, partially for concerns of neurotoxicity. Here, we report an international study of fifty-five children and adolescents who received CAR T-cell therapy for relapsed BCP-ALL with CNS involvement at the time of referral. All patients received bridging therapy, 16 still having active CNS disease at the time of lymphodepletion. Twelve patients received CD28-based CAR T-cells, 9 being subsequently treated with allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Forty-three patients received 4-1BB-based CAR T-cells. Cytokine-release syndrome (CRS) and neurotoxicity occurred in 65% and 38% of patients, respectively, more frequently following treatment with CD28-based CARs. Fifty-one of 54 evaluable patients (94%) achieved complete response following this therapy. Relapse occurred in 22 patients: 19/43 following 4-1BB-based CARs (12 CNS relapses), and 3/12 after CD28-based CARs with subsequent HSCT (no CNS relapse). Patients treated with tisagenlecleucel for an isolated CNS relapse had a high incidence of a subsequent CNS relapse (6 of 8). CAR T-cells were found to be effective in this cohort, though the risk of CNS relapse was not completely mitigated by this approach.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Jacoby E, Ghorashian S, Vormoor B, et al. CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia. 2022. PMID: 35468946. doi:10.1038/s41375-022-01546-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。